Skip to main content
Signal8

Zimmer Biomet Announces Third Quarter 2026 Financial Results

$ZBHPress releaseNov 4, 2026, 6:30 AM ETRead the release

Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, up 3.1% reported and 3.7% constant currency, with diluted EPS of $1.00 (down 13.8%) and adjusted EPS of $1.90, flat year-over-year. Diversification franchises carried the quarter: Hips grew 6.0%, S.E.T. 6.8%, and Technology & Data/Bone Cement/Surgical 11.9%, while Knees declined 3.1%. Free cash flow was $372.4 million on $560.0 million of operating cash flow.

Key figures

Eps
1
Revenue
2062900000
Guidance
FY2026 reported revenue change 4.4%-4.9% (from 3.9%-4.9%); constant currency revenue 4.1%-4.6% (from 3.4%-4.4%); organic constant currency 3.0%-3.5% (from 2.25%-3.25%); adjusted diluted EPS $8.50-$8.60 (from $8.47-$8.59)
Revenue Yoy
3.1%
Fcf
372400000
Adjusted eps
1.9
Net earnings
191600000
Hip sales change
6.0%
Set sales change
6.8%
Knee sales change
-3.1%
Operating cash flow
560000000
Adjusted net earnings
362800000
Tech data cement surgical change
11.9%

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    ZBH: Zimmer Biomet Announces Third Quarter 2026 Financial Results — AI Analysis | Signal8